The narrative challenges the idea that extended survival equates to sufficient time, emphasizing the profound loss of a young ...

Vaccines are particularly exciting because they can train the immune system to seek out and destroy these microscopic cancer ...

Dr. Amany Keruakous sat down for an interview with CURE, in which she discussed how bispecific antibodies for multiple ...

Emotional readiness often lags behind intellectual awareness, leaving individuals unprepared for a cancer diagnosis. Support ...

When Gleevec was invented, or when it came out, that was a game-changer for patients with GIST, because they previously had ...

One of biggest stories or developments in acute myeloid leukemia or AML is the wider adoption and use of the regimen of ...

TARA-002 demonstrates high complete response rates in BCG-naïve NMIBC patients, with 72% achieving CR and 50% maintaining it ...

The U.S. Food and Drug Administration (FDA) has granted traditional approval to Jaypirca (pirobrutinib) for the treatment of ...

Dr. Thomas Marron, a medical oncologist whose research focuses on the development of cancer immunotherapies, is the director of the Early Phase Trials Unit at The Tisch Cancer Institute, Professor of ...

The U.S. commercial launch of LYMPHIR (denileukin diftitox-cxdl), a novel cancer immunotherapy for adults with relapsed or ...

The oncologist's innovative thinking and deep knowledge provided hope and improved the patient's quality of life. I’ve lived ...

As part of her journey with stage 3 inflammatory breast cancer, Lindsey Gunter experienced chemotherapy side effects so ...